progesterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
steroids, progestogens	2279	57-83-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: progesterone gestone gestormone glanducorpin lugesteron lugesterone progestan progeston progestone progestron progesterol syngesterone	The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Molecular weight: 314.47 Formula: C21H30O2 CLOGP: 3.96 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 34.14 ALOGS: -4.76 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

progesterone
gestone
gestormone
glanducorpin
lugesteron
lugesterone
progestan
progeston
progestone
progestron
progesterol
syngesterone

The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.

Molecular weight: 314.47
Formula: C21H30O2
CLOGP: 3.96
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 34.14
ALOGS: -4.76
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	g	O
5	mg	P
0.20	g	R
90	mg	V

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	21.20 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 4, 1976	FDA	ALZA
Sept. 27, 2021	PMDA	FUJI PHARMA CO., LTD.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	850.18	12.51	219	25593	3445	56262810
Temperature regulation disorder	432.78	12.51	135	25677	4333	56261922
Food allergy	349.93	12.51	137	25675	8687	56257568
Coeliac disease	328.92	12.51	137	25675	10202	56256053
Immunodeficiency	270.41	12.51	137	25675	16020	56250235
Exposure during pregnancy	267.97	12.51	321	25491	136021	56130234
Bursitis	216.81	12.51	143	25669	27439	56238816
Foetal exposure during pregnancy	203.97	12.51	149	25663	33674	56232581
Maternal exposure during pregnancy	199.68	12.51	331	25481	189222	56077033
Abortion spontaneous	198.93	12.51	163	25649	43590	56222665
Premature labour	185.04	12.51	96	25716	11786	56254469
Rash erythematous	184.77	12.51	146	25666	37075	56229180
Product adhesion issue	158.18	12.51	64	25748	4419	56261836
Premature delivery	155.91	12.51	116	25696	26944	56239311
Fluid retention	150.53	12.51	153	25659	53925	56212330
Hyperhidrosis	144.26	12.51	196	25616	93892	56172363
Upper respiratory tract infection	123.94	12.51	158	25654	71130	56195125
Meningioma	114.76	12.51	48	25764	3606	56262649
Gestational diabetes	113.76	12.51	61	25751	8003	56258252
Premature baby	96.70	12.51	76	25736	19129	56247126
Vaginal haemorrhage	92.94	12.51	84	25728	25589	56240666
Death	91.74	12.51	22	25790	341404	55924851
Autoimmune dermatitis	89.12	12.51	16	25796	33	56266222
Headache	84.23	12.51	489	25323	558555	55707700
Oligohydramnios	80.80	12.51	44	25768	5950	56260305
Erythema	80.66	12.51	203	25609	155736	56110519
Butterfly rash	80.10	12.51	29	25783	1477	56264778
Postmenopausal haemorrhage	78.54	12.51	31	25781	2005	56264250
Pregnancy	76.85	12.51	85	25727	32948	56233307
Hot flush	74.07	12.51	99	25713	46627	56219628
Asthma	73.80	12.51	161	25651	112609	56153646
Haemorrhage in pregnancy	71.88	12.51	28	25784	1748	56264507
Premature rupture of membranes	69.89	12.51	37	25775	4728	56261527
Pre-eclampsia	66.64	12.51	44	25768	8442	56257813
Placenta accreta	65.17	12.51	16	25796	204	56266051
Congenital absence of vertebra	63.64	12.51	12	25800	36	56266219
Toxicity to various agents	63.23	12.51	13	25799	224551	56041704
Maternal exposure before pregnancy	60.04	12.51	38	25774	6785	56259470
Progesterone decreased	58.43	12.51	13	25799	104	56266151
Systemic lupus erythematosus	58.41	12.51	7	25805	180071	56086184
Ectopic pregnancy	57.40	12.51	26	25786	2368	56263887
Off label use	57.34	12.51	443	25369	555737	55710518
Congenital vesicoureteric reflux	55.90	12.51	10	25802	20	56266235
Glossodynia	54.55	12.51	4	25808	152454	56113801
Normal newborn	54.50	12.51	37	25775	7433	56258822
Atrial septal defect	54.19	12.51	35	25777	6471	56259784
Constipation	52.37	12.51	207	25605	201736	56064519
Synovitis	50.55	12.51	7	25805	161298	56104957
Vulvovaginal discomfort	50.39	12.51	23	25789	2132	56264123
Wound	48.65	12.51	4	25808	138800	56127455
Acute kidney injury	48.41	12.51	25	25787	240738	56025517
Drug hypersensitivity	47.41	12.51	250	25562	274955	55991300
Abortion threatened	46.46	12.51	15	25797	538	56265717
Periorbital oedema	45.58	12.51	29	25783	5225	56261030
Pneumonia	44.45	12.51	74	25738	407024	55859231
Ovarian enlargement	44.16	12.51	14	25798	473	56265782
Subdural hygroma	43.88	12.51	12	25800	239	56266016
Gastroschisis	42.75	12.51	12	25800	264	56265991
Back pain	42.59	12.51	218	25594	236952	56029303
Small for dates baby	42.34	12.51	24	25788	3506	56262749
Arthropathy	41.45	12.51	20	25792	200255	56066000
Hormone level abnormal	39.95	12.51	20	25792	2275	56263980
Pericarditis	38.55	12.51	3	25809	108920	56157335
Intermenstrual bleeding	37.96	12.51	29	25783	6998	56259257
Head discomfort	37.11	12.51	36	25776	11978	56254277
Human herpesvirus 6 infection	37.01	12.51	20	25792	2662	56263593
Photosensitivity reaction	36.95	12.51	38	25774	13555	56252700
Foetal death	36.92	12.51	31	25781	8556	56257699
Foetal growth restriction	35.52	12.51	28	25784	7071	56259184
HELLP syndrome	35.22	12.51	14	25798	922	56265333
Ascites	34.70	12.51	62	25750	37482	56228773
Adnexal torsion	34.60	12.51	11	25801	375	56265880
Single umbilical artery	34.49	12.51	10	25802	248	56266007
Uterine haemorrhage	34.39	12.51	21	25791	3519	56262736
Ventricular septal defect	33.82	12.51	22	25790	4116	56262139
Breast hyperplasia	33.68	12.51	10	25802	270	56265985
Tinnitus	33.58	12.51	54	25758	29988	56236267
Completed suicide	33.28	12.51	10	25802	133823	56132432
Hepatic enzyme increased	33.19	12.51	161	25651	171223	56095032
Suicidal behaviour	33.18	12.51	18	25794	2415	56263840
Product odour abnormal	32.78	12.51	14	25798	1107	56265148
Ovarian haemorrhage	31.97	12.51	10	25802	323	56265932
Ophthalmic vein thrombosis	31.28	12.51	9	25803	217	56266038
Blood oestrogen decreased	30.42	12.51	9	25803	240	56266015
Endometrial stromal sarcoma	30.29	12.51	6	25806	25	56266230
Product quality issue	30.09	12.51	53	25759	31683	56234572
Retroplacental haematoma	29.86	12.51	8	25804	147	56266108
Retained placenta or membranes	28.89	12.51	9	25803	287	56265968
Anxiety	28.88	12.51	169	25643	193003	56073252
Caesarean section	28.45	12.51	36	25776	16055	56250200
Neutropenia	28.13	12.51	19	25793	158148	56108107
Vaginal discharge	28.06	12.51	23	25789	6140	56260115
Abortion missed	27.82	12.51	14	25798	1610	56264645
Ovarian cyst	27.47	12.51	34	25778	14832	56251423
Blister	27.31	12.51	8	25804	108879	56157376
Treatment failure	27.06	12.51	23	25789	170369	56095886
Abdominal discomfort	27.00	12.51	54	25758	277220	55989035
Periodic limb movement disorder	26.98	12.51	8	25804	215	56266040
Hypersensitivity	26.69	12.51	205	25607	256203	56010052
Twin pregnancy	26.30	12.51	12	25800	1111	56265144
Sepsis	25.96	12.51	16	25796	139824	56126431
Swelling	25.73	12.51	44	25768	239727	56026528
Decreased appetite	24.67	12.51	39	25773	219192	56047063
Pelvic infection	24.62	12.51	8	25804	293	56265962
Preterm premature rupture of membranes	24.52	12.51	12	25800	1300	56264955
Confusional state	24.41	12.51	36	25776	208119	56058136
Therapeutic product effect decreased	24.40	12.51	25	25787	169427	56096828
Hippocampal sclerosis	24.26	12.51	6	25806	79	56266176
Cardiac arrest	24.26	12.51	5	25807	86309	56179946
Breast tenderness	24.17	12.51	14	25798	2131	56264124
Drug intolerance	23.76	12.51	54	25758	264764	56001491
Talipes	23.45	12.51	12	25800	1430	56264825
Application site pruritus	23.40	12.51	17	25795	3802	56262453
Complication of pregnancy	23.04	12.51	9	25803	566	56265689
Patent ductus arteriosus	22.88	12.51	17	25795	3934	56262321
Product use in unapproved indication	22.88	12.51	126	25686	140696	56125559
Application site erythema	22.71	12.51	18	25794	4582	56261673
Anaemia	22.06	12.51	57	25755	267454	55998801
Subchorionic haematoma	21.78	12.51	6	25806	123	56266132
General physical health deterioration	21.33	12.51	28	25784	169982	56096273
Menopausal symptoms	21.32	12.51	13	25799	2172	56264083
Mediastinal effusion	21.21	12.51	5	25807	53	56266202
Hydrops foetalis	21.00	12.51	8	25804	470	56265785
Product use issue	20.62	12.51	151	25661	185890	56080365
Carnitine deficiency	20.50	12.51	6	25806	154	56266101
Congenital umbilical hernia	20.36	12.51	7	25805	306	56265949
Lower respiratory tract infection	20.13	12.51	14	25798	114780	56151475
Application site rash	20.09	12.51	13	25799	2410	56263845
Eosinophilic pneumonia acute	19.91	12.51	7	25805	327	56265928
Cholestasis of pregnancy	19.70	12.51	10	25802	1171	56265084
Ultrasound liver abnormal	19.59	12.51	4	25808	20	56266235
Tubo-ovarian abscess	19.45	12.51	7	25805	350	56265905
Ovarian abscess	19.18	12.51	6	25806	194	56266061
Temporal lobe epilepsy	18.92	12.51	7	25805	379	56265876
Drug abuse	18.83	12.51	4	25808	67606	56198649
Oestradiol increased	18.81	12.51	5	25807	89	56266166
Abdominal pain lower	18.66	12.51	36	25776	23056	56243199
Hypogonadism	18.61	12.51	5	25807	93	56266162
Peripheral swelling	18.60	12.51	51	25761	234675	56031580
Renal impairment	18.37	12.51	7	25805	80706	56185549
Prescribed overdose	18.31	12.51	35	25777	22261	56243994
Therapeutic response unexpected	18.18	12.51	30	25782	17014	56249241
Feeling abnormal	18.12	12.51	114	25698	133488	56132767
Postpartum haemorrhage	18.04	12.51	11	25801	1838	56264417
Infection	17.80	12.51	41	25771	200165	56066090
Cardiac failure congestive	17.77	12.51	9	25803	87711	56178544
Uterine haematoma	17.76	12.51	4	25808	34	56266221
Breast enlargement	17.70	12.51	10	25802	1451	56264804
Malignant neoplasm progression	17.40	12.51	6	25806	73581	56192674
Cardiac failure	17.27	12.51	8	25804	82085	56184170
Endometrial hyperplasia	17.16	12.51	8	25804	778	56265477
Feeling hot	17.14	12.51	50	25762	41737	56224518
Turner's syndrome	17.13	12.51	5	25807	127	56266128
Gastrointestinal haemorrhage	16.61	12.51	7	25805	75944	56190311
Application site irritation	16.56	12.51	10	25802	1642	56264613
Enlarged clitoris	16.31	12.51	5	25807	151	56266104
Renal failure	16.25	12.51	16	25796	110484	56155771
Joint swelling	16.23	12.51	73	25739	289727	55976528
Biochemical pregnancy	16.17	12.51	3	25809	8	56266247
Stomatitis	16.09	12.51	19	25793	120791	56145464
Premature separation of placenta	15.98	12.51	10	25802	1750	56264505
Injection site pain	15.92	12.51	100	25712	117018	56149237
Haemoglobin decreased	15.91	12.51	23	25789	134114	56132141
Palatal polyp	15.91	12.51	3	25809	9	56266246
Primary hypogonadism	15.88	12.51	5	25807	165	56266090
Folliculitis	15.83	12.51	3	25809	54976	56211279
Incorrect dose administered	15.34	12.51	56	25756	52491	56213764
Product taste abnormal	15.34	12.51	10	25802	1878	56264377
Hypotension	15.32	12.51	61	25751	250447	56015808
Live birth	15.15	12.51	30	25782	19575	56246680
Swelling face	14.92	12.51	58	25754	56011	56210244
Fallopian tube disorder	14.83	12.51	6	25806	414	56265841
Retinal vein occlusion	14.77	12.51	10	25802	1998	56264257
Wheezing	14.75	12.51	8	25804	75018	56191237
Product physical issue	14.66	12.51	14	25798	4568	56261687
Disease progression	14.59	12.51	16	25796	105157	56161098
Arterial intramural haematoma	14.53	12.51	3	25809	16	56266239
Idiopathic angioedema	14.53	12.51	3	25809	16	56266239
Heterotopic pregnancy	14.53	12.51	3	25809	16	56266239
Pulmonary oedema	14.29	12.51	3	25809	51140	56215115
Endometrial cancer stage I	14.25	12.51	5	25807	232	56266023
Dyspnoea	14.24	12.51	189	25623	592388	55673867
Keratoconus	14.23	12.51	3	25809	18	56266237
Blood oestrogen increased	14.21	12.51	4	25808	89	56266166
Nerve compression	14.05	12.51	18	25794	8126	56258129
Infusion related reaction	13.99	12.51	49	25763	208882	56057373
Foetal hypokinesia	13.98	12.51	6	25806	480	56265775
Irritable bowel syndrome	13.90	12.51	7	25805	68451	56197804
Drug exposure before pregnancy	13.88	12.51	7	25805	809	56265446
Foreign body in reproductive tract	13.80	12.51	6	25806	496	56265759
Anti-Muellerian hormone level decreased	13.77	12.51	4	25808	100	56266155
Application site urticaria	13.76	12.51	5	25807	257	56265998
Chorioretinopathy	13.73	12.51	7	25805	827	56265428
Abortion	13.67	12.51	10	25802	2259	56263996
Febrile neutropenia	13.63	12.51	17	25795	105528	56160727
Erythema nodosum	13.58	12.51	13	25799	4252	56262003
Liver tenderness	13.58	12.51	4	25808	105	56266150
Impaired healing	13.44	12.51	12	25800	86829	56179426
Vomiting	13.43	12.51	155	25657	498073	55768182
Product substitution issue	13.34	12.51	24	25788	14575	56251680
Embedded device	13.27	12.51	11	25801	2982	56263273
Placental insufficiency	13.11	12.51	8	25804	1338	56264917
Chronic obstructive pulmonary disease	13.03	12.51	5	25807	57410	56208845
Abdominal distension	12.96	12.51	70	25742	77556	56188699
Muscle injury	12.90	12.51	4	25808	52496	56213759
Platelet count decreased	12.85	12.51	18	25794	106365	56159890
Meningioma benign	12.75	12.51	5	25807	318	56265937
Cervical incompetence	12.73	12.51	6	25806	598	56265657
Low birth weight baby	12.68	12.51	15	25797	6243	56260012
Birth mark	12.65	12.51	4	25808	134	56266121
Eosinophilic pneumonia	12.57	12.51	9	25803	1968	56264287

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal exposure during pregnancy	753.46	111.45	185	813	40691	31655655
Premature baby	324.55	111.45	81	917	17985	31678361
Atrial septal defect	138.47	111.45	34	964	6893	31689453

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Ovarian hyperstimulation syndrome	903.12	14.36	203	19095	3037	70906109
Temperature regulation disorder	479.73	14.36	130	19168	4314	70904832
Food allergy	404.25	14.36	132	19166	8392	70900754
Coeliac disease	396.73	14.36	132	19166	8901	70900245
Immunodeficiency	317.99	14.36	134	19164	17421	70891725
Bursitis	276.15	14.36	138	19160	26535	70882611
Exposure during pregnancy	271.45	14.36	210	19088	87507	70821639
Maternal exposure during pregnancy	260.53	14.36	230	19068	115115	70794031
Rash erythematous	200.76	14.36	142	19156	51576	70857570
Fluid retention	187.84	14.36	148	19150	63237	70845909
Premature delivery	173.89	14.36	94	19204	21210	70887936
Abortion spontaneous	160.02	14.36	96	19202	26383	70882763
Upper respiratory tract infection	149.45	14.36	143	19155	79131	70830015
Premature labour	134.65	14.36	58	19240	7942	70901204
Hyperhidrosis	132.67	14.36	171	19127	131415	70777731
Gestational diabetes	122.78	14.36	50	19248	5951	70903195
Headache	119.19	14.36	387	18911	580018	70329128
Asthma	107.92	14.36	148	19150	120645	70788501
Meningioma	105.12	14.36	40	19258	3978	70905168
Butterfly rash	96.44	14.36	29	19269	1401	70907745
Erythema	92.86	14.36	182	19116	199381	70709765
Autoimmune dermatitis	87.12	14.36	15	19283	46	70909100
Death	86.47	14.36	17	19281	510044	70399102
Haemorrhage in pregnancy	85.50	14.36	26	19272	1305	70907841
Hepatic enzyme increased	85.25	14.36	153	19145	156837	70752309
Vaginal haemorrhage	83.85	14.36	58	19240	20294	70888852
Pre-eclampsia	83.53	14.36	39	19259	6446	70902700
Premature rupture of membranes	78.11	14.36	32	19266	3866	70905280
Drug hypersensitivity	76.78	14.36	199	19099	262260	70646886
Normal newborn	75.35	14.36	36	19262	6264	70902882
Placenta accreta	74.22	14.36	16	19282	194	70908952
Acute kidney injury	74.04	14.36	19	19279	474605	70434541
Back pain	72.65	14.36	199	19099	270953	70638193
Product adhesion issue	69.19	14.36	26	19272	2498	70906648
Toxicity to various agents	68.50	14.36	11	19287	382161	70526985
Maternal exposure before pregnancy	65.31	14.36	28	19270	3788	70905358
Constipation	62.43	14.36	180	19118	252258	70656888
Hypersensitivity	60.86	14.36	168	19130	229644	70679502
Ovarian enlargement	55.54	14.36	14	19284	347	70908799
Abortion threatened	53.50	14.36	14	19284	404	70908742
Periorbital oedema	49.06	14.36	29	19269	7746	70901400
Head discomfort	48.73	14.36	35	19263	12988	70896158
HELLP syndrome	46.09	14.36	14	19284	700	70908446
Ectopic pregnancy	45.66	14.36	17	19281	1591	70907555
Progesterone decreased	44.62	14.36	8	19290	33	70909113
Hot flush	44.59	14.36	61	19237	49523	70859623
Vulvovaginal discomfort	41.58	14.36	16	19282	1639	70907507
Breast hyperplasia	40.55	14.36	9	19289	126	70909020
Off label use	40.47	14.36	342	18956	742718	70166428
Photosensitivity reaction	40.45	14.36	37	19261	19303	70889843
Uterine haemorrhage	40.42	14.36	18	19280	2666	70906480
Pregnancy	39.37	14.36	40	19258	23741	70885405
Rheumatoid arthritis	39.04	14.36	170	19128	291635	70617511
Pneumonia	38.95	14.36	64	19234	596168	70312978
Ovarian haemorrhage	37.71	14.36	10	19288	304	70908842
Ophthalmic vein thrombosis	35.40	14.36	9	19289	231	70908915
Neutropenia	35.17	14.36	13	19285	257143	70652003
Suicidal behaviour	35.14	14.36	17	19281	3039	70906107
Fatigue	35.12	14.36	360	18938	823959	70085187
Tinnitus	34.81	14.36	46	19252	36130	70873016
Completed suicide	33.66	14.36	10	19288	227125	70682021
Pain	33.43	14.36	288	19010	628528	70280618
Adnexal torsion	32.89	14.36	9	19289	309	70908837
Postmenopausal haemorrhage	32.76	14.36	13	19285	1446	70907700
Cardiac arrest	32.51	14.36	3	19295	159831	70749315
Twin pregnancy	31.71	14.36	11	19287	840	70908306
Foetal death	31.04	14.36	20	19278	6219	70902927
Retroplacental haematoma	30.49	14.36	7	19291	115	70909031
Contraindicated product administered	30.37	14.36	93	19205	134519	70774627
Hormone level abnormal	30.19	14.36	13	19285	1777	70907369
Caesarean section	29.89	14.36	25	19273	11582	70897564
Ascites	29.41	14.36	60	19238	67487	70841659
Drug abuse	29.33	14.36	3	19295	147253	70761893
Intermenstrual bleeding	29.04	14.36	18	19280	5232	70903914
Oligohydramnios	28.40	14.36	15	19283	3225	70905921
Pelvic infection	28.25	14.36	8	19290	312	70908834
Endometrial stromal sarcoma	28.01	14.36	5	19293	20	70909126
Foetal exposure during pregnancy	27.85	14.36	18	19280	5627	70903519
Product odour abnormal	27.75	14.36	11	19287	1220	70907926
Menopausal symptoms	27.44	14.36	12	19286	1702	70907444
Ovarian abscess	27.24	14.36	6	19292	81	70909065
Sepsis	26.40	14.36	17	19281	244528	70664618
Oestradiol increased	26.35	14.36	6	19292	95	70909051
Foetal growth restriction	26.14	14.36	12	19286	1907	70907239
Retained placenta or membranes	26.12	14.36	7	19291	222	70908924
Ovarian cyst	25.56	14.36	23	19275	11749	70897397
Prescribed overdose	25.28	14.36	34	19264	27147	70881999
Swelling face	25.05	14.36	54	19244	63110	70846036
Synovitis	24.80	14.36	3	19295	129225	70779921
Anaemia	24.75	14.36	45	19253	403378	70505768
Preterm premature rupture of membranes	24.46	14.36	10	19288	1201	70907945
Abdominal pain lower	24.29	14.36	34	19264	28182	70880964
Mediastinal effusion	23.64	14.36	5	19293	55	70909091
Tubo-ovarian abscess	23.61	14.36	7	19291	322	70908824
Decreased appetite	23.53	14.36	29	19269	304751	70604395
Renal failure	23.52	14.36	11	19287	189059	70720087
Product use issue	23.40	14.36	104	19194	179833	70729313
Complication of pregnancy	23.26	14.36	7	19291	339	70908807
Hypotension	23.15	14.36	47	19251	404334	70504812
Confusional state	23.09	14.36	26	19272	284372	70624774
Cholestasis of pregnancy	23.04	14.36	9	19289	960	70908186
Postpartum haemorrhage	22.33	14.36	10	19288	1501	70907645
Feeling hot	22.10	14.36	44	19254	48626	70860520
Hirsutism	22.06	14.36	9	19289	1075	70908071
Hypotonia neonatal	22.02	14.36	5	19293	78	70909068
Renal impairment	21.94	14.36	6	19292	143931	70765215
Injection site pain	21.79	14.36	76	19222	117543	70791603
Porphyria non-acute	21.62	14.36	8	19290	736	70908410
Febrile neutropenia	20.98	14.36	15	19283	204303	70704843
Uterine haematoma	20.79	14.36	4	19294	26	70909120
Carnitine deficiency	20.54	14.36	6	19292	262	70908884
Gastrointestinal haemorrhage	20.43	14.36	6	19292	137402	70771744
Cardiac failure	20.05	14.36	7	19291	143534	70765612
Anxiety	19.95	14.36	115	19183	220215	70688931
Breast enlargement	19.94	14.36	9	19289	1375	70907771
Nephrocalcinosis	19.84	14.36	9	19289	1392	70907754
Blood oestrogen decreased	19.50	14.36	5	19293	133	70909013
Bradycardia	19.36	14.36	5	19293	124610	70784536
Vaginal discharge	18.83	14.36	13	19285	4530	70904616
Placental insufficiency	18.79	14.36	8	19290	1063	70908083
Fallopian tube disorder	18.52	14.36	6	19292	371	70908775
Primary hypogonadism	18.26	14.36	5	19293	172	70908974
Abortion missed	17.91	14.36	8	19290	1193	70907953
Congenital hydronephrosis	17.47	14.36	3	19295	9	70909137
Live birth	17.24	14.36	20	19278	13759	70895387
Ovarian cyst ruptured	16.92	14.36	7	19291	867	70908279
Malignant neoplasm progression	16.89	14.36	6	19292	121733	70787413
Hydrops foetalis	16.70	14.36	5	19293	238	70908908
Erythema nodosum	16.66	14.36	12	19286	4469	70904677
Cardiac failure congestive	16.66	14.36	8	19290	135449	70773697
Eosinophilic pneumonia acute	16.53	14.36	7	19291	918	70908228
Product taste abnormal	16.24	14.36	9	19289	2127	70907019
Embedded device	16.22	14.36	10	19288	2879	70906267
Heterotopic pregnancy	16.10	14.36	3	19295	16	70909130
Systemic lupus erythematosus	16.00	14.36	4	19294	101898	70807248
Genital haemorrhage	15.97	14.36	13	19285	5802	70903344
Failed induction of labour	15.91	14.36	5	19293	280	70908866
Nerve compression	15.85	14.36	15	19283	8163	70900983
Anti-Muellerian hormone level decreased	15.83	14.36	4	19294	100	70909046
Depressed mood	15.72	14.36	36	19262	43784	70865362
Cardio-respiratory arrest	15.71	14.36	4	19294	100673	70808473
General physical health deterioration	15.67	14.36	25	19273	236006	70673140
Retinal vein occlusion	15.53	14.36	10	19288	3106	70906040
Subchorionic haematoma	15.50	14.36	4	19294	109	70909037
Haemoglobin decreased	15.33	14.36	20	19278	205139	70704007
Drug interaction	15.23	14.36	53	19245	381388	70527758
Idiopathic angioedema	14.83	14.36	3	19295	26	70909120
Platelet count decreased	14.78	14.36	16	19282	178206	70730940

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Human herpesvirus 6 infection	46.81	37.71	15	363	45	89369
Congestive cardiomyopathy	40.41	37.71	14	364	57	89357

Pharmacologic Action:

Source	Code	Description
ATC	G03DA04	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Pregnen (4) derivatives
ATC	G03FA04	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations
FDA CS	M0017672	Progesterone
FDA EPC	N0000175601	Progesterone
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D009466	Neuromuscular Blocking Agents
MeSH PA	D003473	Neuromuscular Nondepolarizing Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D006728	Hormones
MeSH PA	D011372	Progestins
CHEBI has role	CHEBI:49323	contraceptive drugs
CHEBI has role	CHEBI:59826	progestins
CHEBI has role	CHEBI:70709	progesterone receptor agonists
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Contraception	indication	13197004
Dysfunctional uterine bleeding	indication	19155002
Atrophic vaginitis	indication	52441000
Secondary physiologic amenorrhea	indication	86030004
Secondary malignant neoplasm of kidney	indication	94360002
Postmenopausal osteoporosis	indication	102447009
Endometriosis	indication	129103003
Menopausal flushing	indication	198436008
Endometrial carcinoma	indication	254878006	DOID:2871
Infertility Secondary to Progesterone Deficiency	indication
Amenorrhea Secondary to Ovarian Dysfunction	indication
Endometrial Hyperplasia Prevention	indication
Prevention of Premature Labor	indication
Corpus Luteum Insufficiency Syndrome	indication
Polycystic ovaries	off-label use	69878008
Menorrhagia	off-label use	386692008
Precocious puberty	off-label use	400179000
Female Hormonal Imbalance	off-label use
Endogenous Estrogen Production Test	off-label use
Hyperlipoproteinemia	contraindication	3744001	DOID:1168
Hypocalcemia	contraindication	5291005
Alcoholism	contraindication	7200002
Weight gain finding	contraindication	8943002
Impaired glucose tolerance	contraindication	9414007
Hypercholesterolemia	contraindication	13644009
Jaundice	contraindication	18165001
Myocardial infarction	contraindication	22298006	DOID:5844
Fibroadenosis of breast	contraindication	23260002	DOID:10352
Diplopia	contraindication	24982008
Retinal hemorrhage	contraindication	28998008
Ectopic pregnancy	contraindication	34801009	DOID:0060329
Depressive disorder	contraindication	35489007
Chloasma	contraindication	36209000
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Mild pre-eclampsia	contraindication	41114007
Body fluid retention	contraindication	43498006
Thrombosis of retinal vein	contraindication	46085004
Humoral hypercalcemia of malignancy	contraindication	47709007
Chronic heart failure	contraindication	48447003
Dementia	contraindication	52448006
Hepatic porphyria	contraindication	55056006	DOID:3133
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Hyperlipidemia	contraindication	55822004	DOID:1168
Anorexia nervosa	contraindication	56882008	DOID:8689
Hepatic failure	contraindication	59927004
Cerebrovascular disease	contraindication	62914000	DOID:6713
Thrombophlebitis	contraindication	64156001	DOID:3875
Osteoporosis	contraindication	64859006	DOID:11476
Intermenstrual bleeding - irregular	contraindication	64996003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Breast lump	contraindication	89164003
Kidney disease	contraindication	90708001	DOID:557
Malignant neoplasm of liver	contraindication	93870000	DOID:3571
Uterine leiomyoma	contraindication	95315005	DOID:13223
Neoplasm of liver	contraindication	126851005	DOID:3571
Deep venous thrombosis	contraindication	128053003
Seizure disorder	contraindication	128613002
Incomplete miscarriage	contraindication	156072005
Bed-ridden	contraindication	160685001
Mammography abnormal	contraindication	168750009
Asthma	contraindication	195967001	DOID:2841
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Chorea	contraindication	271700006
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Osteopenia	contraindication	312894000
Functional visual loss	contraindication	313165001
Malignant tumor of ovary	contraindication	363443007	DOID:2394
Thromboembolic disorder	contraindication	371039008
Cardiovascular event risk	contraindication	395112001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Porphyria	contraindication	418470004
Optic disc edema	contraindication	423341008	DOID:146
Family history of malignant neoplasm of breast	contraindication	429740004
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002
Predisposition to Thrombosis	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Cattle	Estrus synchronization	Indication
Cattle	Induction of estrous cycles	Indication
Cattle	Synchronization of the return to estrus	Indication
Cattle	Advancement of first postpartum estrus	Indication
Cattle	Advancement of first pubertal estrus	Indication
Cattle	To increase rate of weight gain	Indication
Cattle	To improve feed efficiency	Indication
Sheep	Estrus induction	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Synovex C, Synovex S	Zoetis Inc.	2
Component E-C with Tylan, Component E-S with Tylan	Elanco US Inc.	3
EAZI-BREED CIDR Cattle Insert	Zoetis Inc.	1
EAZI-BREED CIDR Sheep Insert	Zoetis Inc.	1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1.78GM	MILPROSA	FERRING PHARMS INC	N201110	April 29, 2020	DISCN	SYSTEM	VAGINAL	10548904	Feb. 3, 2029	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
1.78GM	MILPROSA	FERRING PHARMS INC	N201110	April 29, 2020	DISCN	SYSTEM	VAGINAL	8580293	Jan. 21, 2030	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	10206932	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	10675288	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	11033626	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	8846648	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	8846649	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	8933059	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	9114145	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	9114146	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Dec. 28, 2021	DISCN	CAPSULE	ORAL	9301920	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	10206932	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	10675288	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	10806740	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	11033626	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	11103513	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	8846648	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	8846649	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	9006222	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	9114145	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	9114146	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG	BIJUVA	THERAPEUTICSMD INC	N210132	Oct. 28, 2018	RX	CAPSULE	ORAL	9301920	Nov. 21, 2032	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1.78GM	MILPROSA	FERRING PHARMS INC	N201110	April 29, 2020	DISCN	SYSTEM	VAGINAL	April 29, 2023	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	AGONIST	ED50	9.88	WOMBAT-PK	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.59	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.32	CHEMBL
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	7.52	CHEMBL
Mineralocorticoid receptor	Nuclear hormone receptor	P08235	MCR_HUMAN		EC50	11	WOMBAT-PK
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN				WOMBAT-PK
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		Ki	8.07	CHEMBL
Corticosteroid-binding globulin	Secreted	P08185	CBG_HUMAN		Ki	7.38	CHEMBL
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	6.94	CHEMBL
Sterol O-acyltransferase 1	Enzyme	P35610	SOAT1_HUMAN		IC50	4.77	CHEMBL
Fatty acid-binding protein, intestinal	Cytosolic other	P12104	FABPI_HUMAN		Ki	4.70	CHEMBL
Cation channel sperm-associated protein 1	Ion channel	Q8NEC5	CTSR1_HUMAN	ACTIVATOR	EC50	8.11	IUPHAR
Cation channel sperm-associated protein 2	Ion channel	Q96P56	CTSR2_HUMAN	ACTIVATOR	EC50	8.11	IUPHAR
Cation channel sperm-associated protein 3	Ion channel	Q86XQ3	CTSR3_HUMAN	ACTIVATOR	EC50	8.11	IUPHAR
Cation channel sperm-associated protein 4	Ion channel	Q7RTX7	CTSR4_HUMAN	ACTIVATOR	EC50	8.11	IUPHAR
Short transient receptor potential channel 5	Ion channel	Q9UL62	TRPC5_HUMAN	BLOCKER	IC50	5.30	IUPHAR
Sodium/nucleoside cotransporter 1	Transporter	O00337	S28A1_HUMAN		Ki	5.17	DRUG MATRIX
P2X purinoceptor 3	Ion channel	P56373	P2RX3_HUMAN		IC50	5.80	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		IC50	5.81	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Ki	7.57	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	8.44	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor		SGMR1_RAT		Kd	6.62	CHEMBL
Androgen receptor	Transcription factor		ANDR_MOUSE		IC50	7.43	CHEMBL
Progesterone receptor	Transcription factor		PRGR_RABIT		Ki	7.98	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	5.35	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane other		SGMR1_CAVPO		Ki	6.18	CHEMBL
Steroid 5-alpha-reductase	Enzyme		S5A1_RAT S5A2_RAT		IC50	5.80	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT ESR2_RAT		Kd	8.41	CHEMBL

External reference:

ID	Source
4017453	VUID
N0000145841	NUI
D00066	KEGG_DRUG
4017453	VANDF
C0033308	UMLSCUI
CHEBI:17026	CHEBI
STR	PDB_CHEM_ID
CHEMBL103	ChEMBL_ID
DB00396	DRUGBANK_ID
D011374	MESH_DESCRIPTOR_UI
C003549	MESH_SUPPLEMENTAL_RECORD_UI
5994	PUBCHEM_CID
2377	IUPHAR_LIGAND_ID
417	INN_ID
4G7DS2Q64Y	UNII
8727	RXNORM
2110	MMSL
53089	MMSL
5365	MMSL
d00550	MMSL
001290	NDDF
16683002	SNOMEDCT_US
50318003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Crinone	HUMAN PRESCRIPTION DRUG LABEL	1	0023-6150	GEL	45 mg	VAGINAL	NDA	23 sections
Crinone	HUMAN PRESCRIPTION DRUG LABEL	1	0023-6151	GEL	90 mg	VAGINAL	NDA	23 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9725	INJECTION	50 mg	INTRAMUSCULAR	ANDA	13 sections
PROGESTERONE	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3128	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	13 sections
PROGESTERONE	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3128	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	NDA	13 sections
PROGESTERONE	Human Prescription Drug Label	1	10888-7135	CAPSULE	100 mg	ORAL	ANDA	21 sections
PROGESTERONE	Human Prescription Drug Label	1	10888-7136	CAPSULE	200 mg	ORAL	ANDA	21 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-157	CAPSULE	100 mg	ORAL	ANDA	25 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-158	CAPSULE	200 mg	ORAL	ANDA	25 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	17478-766	CAPSULE	100 mg	ORAL	ANDA	23 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	17478-767	CAPSULE	200 mg	ORAL	ANDA	23 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	43598-349	CAPSULE	100 mg	ORAL	ANDA	21 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	43598-350	CAPSULE	200 mg	ORAL	ANDA	21 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2527	CAPSULE	100 mg	ORAL	ANDA	23 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3240	CAPSULE	100 mg	ORAL	NDA	24 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4656	CAPSULE	100 mg	ORAL	ANDA	23 sections
Progesterone	Human Prescription Drug Label	1	50090-5928	CAPSULE	100 mg	ORAL	ANDA	22 sections
Bijuva	HUMAN PRESCRIPTION DRUG LABEL	2	50261-211	CAPSULE	100 mg	ORAL	NDA	33 sections
Progesterone	HUMAN PRESCRIPTION DRUG LABEL	1	53002-1760	CAPSULE	200 mg	ORAL	ANDA	23 sections
Prometrium	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4230	CAPSULE	200 mg	ORAL	NDA	15 sections
Prometrium	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4250	CAPSULE	100 mg	ORAL	NDA	15 sections
Prochieve	HUMAN PRESCRIPTION DRUG LABEL	1	55056-0406	GEL	45 mg	VAGINAL	NDA	24 sections
Crinone	HUMAN PRESCRIPTION DRUG LABEL	1	55056-0806	GEL	90 mg	VAGINAL	NDA	24 sections
Crinone	HUMAN PRESCRIPTION DRUG LABEL	1	55056-0808	GEL	45 mg	VAGINAL	NDA	24 sections
Crinone	HUMAN PRESCRIPTION DRUG LABEL	1	55056-0818	GEL	90 mg	VAGINAL	NDA	24 sections
Prochieve	HUMAN PRESCRIPTION DRUG LABEL	1	55056-1601	GEL	90 mg	VAGINAL	NDA	24 sections
Progesterone	Human Prescription Drug Label	1	55150-306	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	16 sections
Progesterone	Human Prescription Drug Label	1	55150-306	INJECTION, SOLUTION	50 mg	INTRAMUSCULAR	ANDA	16 sections
ENDOMETRIN	HUMAN PRESCRIPTION DRUG LABEL	1	55566-6500	INSERT	100 mg	VAGINAL	NDA	26 sections
ENDOMETRIN	HUMAN PRESCRIPTION DRUG LABEL	1	55566-6500	INSERT	100 mg	VAGINAL	NDA	26 sections